X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Preserving safety-net programs like 340B

By Emilie Signora  |    December 17, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Fact Check: Do contract pharmacies help patients access 340B medicines? No.

By Nicole Longo  |    November 2, 2021
Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New...   Read More

New video: Why changes to the 340B program are essential for patients

By Nicole Longo  |    October 28, 2021
The 340B program is confusing. That’s a fact that likely no one would question. In fact, it is often forgotten in broader discussions about our health care system even though it is the second...   Read More

New analysis adds to research questioning whether 340B is working as Congress intended

By Nicole Longo  |    October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that...   Read More

340B hospitals among those that provide lowest levels of community benefit across the country

By Nicole Longo  |    July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....   Read More

Getting the 340B program back on track in 2021

By Nicole Longo  |    March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...   Read More

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

By Nicole Longo  |    December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...   Read More

Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements

By Nicole Longo  |    December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...   Read More

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

By Nicole Longo  |    November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates